Abstract WP98: Characterizing Cerebral Morphometry Changes and Effects of 3K3A-APC in Ischemic Stroke
Introduction: Acute stroke treatment trials have long used radiological endpoints of infarct size and hemorrhage burden to quantify treatment effect. Automated imaging pipelines analyzing cerebral morphometry have become more ubiquitous and can provide more comprehensive insight by measuring specific brain compartments. We piloted a feasibility study to integrate these imaging analyses into an established multicenter stroke trial, the NeuroNEXT trial NN104 (RHAPSODY), which investigated the effect of 3K3A-APC, a recombinant variant of activated protein C active at PAR-1. Methods: Using a well-validated Advanced Normalization Tools (ANTs) pipeline and the MindBoggle OASIS-30 Atropos template, gross compartments of hemispheric white matter, cortical grey matter, and subcortical grey matter were calculated from MRIs from participants >7 days post stroke. Fourteen participants treated with placebo were included, and eleven treated with 3K3A-APC. Results: Participants treated with placebo had mean volumes of 220.0mL, 276.5mL, and 21.7mL in ipsilateral cortical grey matter, white matter, and subcortical grey matter, respectively. Participants in the treatment arm had mean volumes of 227.4mL, 243.7mL, and 21.4mL. Discussion: We present a novel application of dynamic cerebral morphometry software that can be implemented in future large scale multi center stroke trials. This study is limited by its small sample size, and while no treatment effect was observed in this feasibility study, we plan to further refine our algorithm to include more heterogenous, clinically acquired imaging protocols, define more specific compartments, and to ultimately correlate with clinical outcomes.